leisure time -WSS

leisure time

author：knowledge 2025-09-30 14:08:43 - browse：5

The FDA building -- First Opinion coverage from STAT — Adobe

The Food and Drug Administration said Monday that it has deep reservations about NurOwn, an investigational ALS treatment from BrainStorm Cell Therapeutics, citing a lack of evidence that the medicine works and the company’s failure to demonstrate that it can properly manufacture the product.

In documents disclosed ahead of a Wednesday public hearing on NurOwn’s application for approval, the FDA detailed its problems with a clinical trial that missed its primary objective and noted that BrainStorm submitted “grossly deficient” information on how the medicine is made, voicing “major concerns that the available data do not meet the statutory standard of substantial evidence of effectiveness to support” approval.

BrainStorm filed for approval over the FDA’s protest, insisting that NurOwn has demonstrated benefits for a subset of ALS patients with milder disease. That conclusion, based on an after-the-fact analysis of the company’s failed pivotal trial, has proved polarizing among patients and physicians, with some arguing that the FDA should exercise flexibility in light of the irrevocably fatal nature of ALS and others demanding BrainStorm conduct another clinical trial to demonstrate its benefits.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Medical device lobby: We're tired of waiting on Medicare coverage

hotspot

explore

WSS

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

At ASCO, AstraZeneca reports strong data for breast cancer drug

Letters to First Opinion on caregivers, digital health, and more

ASCO: AstraZeneca says CAR

ASCO: Palliative care found as helpful given virtually as in person

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

Wikipedia

leisure time

focus

How to save PrEP access — and even expand it

Why getting cancer drugs just got harder for rural patients

Jerome Adams on the need for new antivirals for Covid

How to increase colonoscopy rates? Looks like an AI can help

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

ChatGPT in medicine: STAT answers readers' burning questions

At ASCO, AstraZeneca reports strong data for breast cancer drug

Hollywood unions extend contract negotiations for actors

FDA does about

Wikipedia

An inside look at PIPEs, biotech's buzzy new financing tool

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

At ASCO, AstraZeneca reports strong data for breast cancer drug

AstraZeneca loses challenge to Medicare drug price negotiation

Ionis drug prevents swelling attacks due to hereditary angioedema

Innovation in antibiotics is ailing. 'Brain drain' may kill it

focus

hotspot

explore

focus